argenx   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Breda Netherlands (2009)

Organization Overview

First Clinical Trial
2013
NCT01813539
First Marketed Drug
2021
efgartigimod (Vyvgart)
First NDA Approval
2021
efgartigimod (Vyvgart)
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

argenx | Argenx BV | ARGENX BV | argenx BVBA | arGEN-X BVBA

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Myelomonocytic, Chronic (Phase 2)

Leukemia, Myelomonocytic, Juvenile (Phase 2)

Muscle Weakness (Phase 3)

Myasthenia Gravis (Phase 3)

Myelodysplastic Syndromes (Phase 2)

Nasopharyngeal Carcinoma (Phase 1)

Neoplasms (Phase 1)

Paresis (Phase 3)

Pemphigus (Phase 3)

Polyneuropathies (Phase 2)

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (Phase 2)

Preleukemia (Phase 2)

Purpura, Thrombocytopenic, Idiopathic (Phase 3)

Syndrome (Phase 2)

Thrombocytopenia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 50
  • # of Trial APIs: 11